Drug Profile
AMTX 036
Alternative Names: AMTX-036; KDT-501Latest Information Update: 15 Jun 2022
Price :
$50
*
At a glance
- Originator KinDex Pharmaceuticals
- Developer Amaro Therapeutics; KinDex Pharmaceuticals
- Class Alkanes; Anti-inflammatories; Antihyperglycaemics; Cyclopentanes; Esters; Ketones; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Polycystic ovary syndrome
- Discontinued Inflammation; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 27 May 2022 Discontinued - Preclinical for Inflammation in USA (PO)
- 27 May 2022 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (unspecified route)
- 26 May 2022 Amaro Therapeutics acquires AMTX 036 from KinDex Pharmaceuticals (Company communication)